Search publications

Publications

  • Rubio-San-Simón A, Hladun Alvaro R, Juan Ribelles A, Castañeda-Heredia A, Guerra-García P, Verdú-Amorós J, Andrés M, Cañete A, Rives-Sola S, Pérez-Martínez A, Mora J, Patiño-García A, Lassaleta A, Llort A, Ramírez M, Mata C, Gallego S, Martín-Broto J, Cruz-Martínez O, Morales-La Madrid A, Solano P, Martínez Romera I, Fernández-Teijeiro A, Bautista F and Moreno L.

    The paediatric cancer clinical research landscape in Spain: a 13-year multicentre experience of the new agents group of the Spanish Society of Paediatric Haematology and Oncology (SEHOP).

    CLINICAL & TRANSLATIONAL ONCOLOGY . 23(12): 2489-2496.

    [doi:10.1007/s12094-021-02649-y]

  • Mora J, Castañeda-Heredia A, Gorostegui M, Santa-María V, Garraus-Oneca M, Muñoz JP, Varo A, Pérez-Jaume S and Mañe S.

    Naxitamab combined with granulocyte-macrophage colony-stimulating factor as consolidation for high-risk neuroblastoma patients in complete remission.

    PEDIATRIC BLOOD & CANCER . 68(10): e29121.

    [doi:10.1002/pbc.29121]

  • Castillo-Ecija H, Pascual-Pastó G, Pérez-Jaume S, Resa-Pares C, Vilà-Ubach M, Monterrubio C, Jimenez-Cabaco A, Baulenas-Farres M, Muñoz-Aznar O, Salvador-Marcos N, Cuadrado-Vilanova M, Gene-Olaciregui N, Balaguer-Lluna L, Burgueño V, Vicario FJ, Manzanares-Quintela A, Castañeda-Heredia A, Santa-María López V, Cruz-Martínez O, Celis-Passini V, Morales-La Madrid A, Garraus-Oneca M, Gorostegui M, Vancells M, Carrasco-Torrents R, Krauel L, Torner-Rubies F, Suñol M, Lavarino C, Mora J and Carcaboso AM.

    Prognostic value of patient-derived xenograft engraftment in pediatric sarcomas.

    JOURNAL OF PATHOLOGY CLINICAL RESEARCH . 7(4): 338-349.

    [doi:10.1002/cjp2.210]

  • Mora J, Castañeda-Heredia A, Colombo MC, Gorostegui M, Fernando Gómez Muñoz, Mañe S, Santa-María López V, Garraus-Oneca M, Macias N, Pérez-Jaume S, Muñoz O, Muñoz JP, Ignacio Barber Martínez de la Torre and Suñol M.

    Clinical and Pathological Evidence of Anti-GD2 Immunotherapy Induced Differentiation in Relapsed/Refractory High-Risk Neuroblastoma.

    Cancers . 13(6): .

    [doi:10.3390/cancers13061264]

  • Rubio-San-Simón A, Verdú-Amorós J, Hladun R, Juan-Ribelles A, Molero M, Guerra-García P, Pérez-Martínez A, Castañeda-Heredia A, Cañete A, de Rojas T, Moreno L and Bautista F.

    Challenges in early phase clinical trials for childhood cancer during the COVID-19 pandemic: a report from the new agents group of the Spanish Society of Paediatric Haematology and Oncology (SEHOP).

    CLINICAL & TRANSLATIONAL ONCOLOGY . 23(1): 183-189. Number of citations: 6

    [doi:10.1007/s12094-020-02399-3]

  • Rubio-San-Simón A, André N, Cefalo MG, Aerts I, Castañeda-Heredia A, Benezech S, Makin G, van Eijkelenburg N, Nysom K, Marshall L, Gambart M, Hladun R, Rossig C, Bergamaschi L, Fagioli F, Carpenter B, Ducassou S, Owens C, Øra I, Ribelles AJ, De Wilde B, Guerra-García P, Strullu M, Rizzari C, Ek T, Hettmer S, Gerber NU, Rawlings C, Diezi M, Palmu S, Ruggiero A, Verdú J, de Rojas T, Vassal G, Geoerger B, Moreno L and Bautista F.

    Impact of COVID-19 in paediatric early-phase cancer clinical trials in Europe: A report from the Innovative Therapies for Children with Cancer (ITCC) consortium.

    EUROPEAN JOURNAL OF CANCER . 141: 82-91.

    [doi:10.1016/j.ejca.2020.09.024]

  • Mora J, Castañeda-Heredia A, Flores MA, Santa-María V, Garraus-Oneca M, Gorostegui M, Simao M, Pérez-Jaume S and Mañe S.

    The Role of Autologous Stem-Cell Transplantation in High-Risk Neuroblastoma Consolidated by anti-GD2 Immunotherapy. Results of Two Consecutive Studies.

    FRONTIERS IN PHARMACOLOGY . 11: 575009-575009. Number of citations: 1

    [doi:10.3389/fphar.2020.575009]

  • Castillo-Ecija H, Monterrubio C, Pascual-Pastó G, Gomez-Gonzalez S, Garcia-Dominguez DJ, Hontecillas-Prieto L, Resa-Pares C, Burgueño V, Paco-Mercader S, Gene-Olaciregui N, Vilà-Ubach M, Restrepo-Perdomo C, Cuadrado-Vilanova M, Balaguer-Lluna L, Pérez-Jaume S, Castañeda-Heredia A, Santa-María López V, Roldan M, Suñol M, de Alava E, Mora J, Lavarino C and Carcaboso AM.

    Treatment-driven selection of chemoresistant Ewing sarcoma tumors with limited drug distribution.

    JOURNAL OF CONTROLLED RELEASE . 324: 440-449. Number of citations: 2

    [doi:10.1016/j.jconrel.2020.05.032]

  • Fernández-Rodríguez J, Morales-La Madrid A, Gel B, Castañeda-Heredia A, Salvador-Hernandez H, Martínez-Iniesta M, Moutinho C, Morata J, Heyn H, Blanco I, Creus-Bachiller E, Capella G, Farré L, Vidal A, Soldado F, Krauel L, Suñol M, Serra E, Villanueva A and Lázaro C.

    Use of patient derived orthotopic xenograft models for real-time therapy guidance in a pediatric sporadic malignant peripheral nerve sheath tumor.

    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY . 12: 1758835920929579. Number of citations: 1

    [doi:10.1177/1758835920929579]

  • Ding YY, Panzer J, Maris JM, Castañeda-Heredia A, Marta Gómez Chiari and Mora J.

    Transverse myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with high-risk neuroblastoma: A case series.

    PEDIATRIC BLOOD & CANCER . 65(1): e26732. Number of citations: 10

    [doi:10.1002/pbc.26732]